ライフサイエンスコーパス: depalmitoylation

1 hile providing new reagents to study protein depalmitoylation.

2 a process that must be balanced precisely by depalmitoylation.

3 rch by emphasizing the necessity of balanced depalmitoylation.

4 ids in a process dependent on GluN2B subunit depalmitoylation.

5 tate inactivation and ablates sensitivity to depalmitoylation.

6 APTs are the only enzymes known to promote depalmitoylation.

7 L115R mutation and were depleted by chemical depalmitoylation.

8 ntity to APT1, that also controls BK channel depalmitoylation.

9 almitoylation-dependent fashion and promotes depalmitoylation.

10 ate the import of R7BP into the nucleus upon depalmitoylation.

11 ma membrane to the Golgi as a consequence of depalmitoylation.

12 Equally important is the mechanism of depalmitoylation.

13 he enzyme more susceptible to APT1-catalyzed depalmitoylation.

14 protein thioesterase 1 (APT1) regulates eNOS depalmitoylation.

15 ts target enables temporal control of target depalmitoylation.

16 ce our basic understanding of the purpose of depalmitoylation.

17 Cln5 shows cysteine palmitoyl thioesterase S-depalmitoylation activity, which was explored via fluore

18 alytic triad Cys(280)-His(166)-Glu(183) in S-depalmitoylation activity.

19 efficient cysteine palmitoyl thioesterase (S-depalmitoylation) activity using fluorescent substrates.

20 Protein palmitoylation and depalmitoylation alter protein function.

21 -Jun N-terminal kinase, resulting in Galphai depalmitoylation and enhanced receptor-Galphai associati

22 aspanin palmitoylation, and underscoring how depalmitoylation and EWI-2 association may collaborate t

23 ation switch, and ligand engagement leads to depalmitoylation and lysosomal degradation.

24 receptors through the combined processes of depalmitoylation and palmitoylation.

25 D17 catalytic activity is required for N-Ras depalmitoylation and re-localization to internal cellula

26 We propose that a cycle of depalmitoylation and repalmitoylation regulates the time

27 rt a role for APT1 in the regulation of eNOS depalmitoylation and suggest that Ca(2+)-CaM activation

28 ts such as bradykinin, which promotes enzyme depalmitoylation and translocation from caveolae.

29 Depalmitoylation and translocation of eNOS modulate the

30 s likely to mediate receptor-induced alpha s depalmitoylation and translocation of the protein to cyt

31 d that the Ca(2+) challenge induced receptor depalmitoylation, and single-channel analysis revealed t

32 thways that regulate eNOS palmitoylation and depalmitoylation are poorly understood.

33 namics in cells and confirms enzyme-mediated depalmitoylation as a critical regulatory mechanism for

34 X6 recruitment and oxidation-induced Galphai depalmitoylation as an additional mechanism of Galphai-G

35 mitoylating enzyme APT1 blocks Wnt5a-induced depalmitoylation, asymmetric MCAM localization, and cell

36 nstrate that APT1 not only catalyzes its own depalmitoylation but also that of APT2 promoting dynamic

37 s such as Palmostatin M (Palm M) block N-Ras depalmitoylation, but lack specificity and target severa

38 alpha s, but not alpha s-GTP[gamma S], from depalmitoylation by a recombinant esterase.

39 brain proteins are highly palmitoylated and depalmitoylation by PPT is essential for their effective

40 transferases zDHHC9/14/18 and is followed by depalmitoylation by the plasma membrane-localized acyl-p

41 including peptide palmitoylation by PAT(s), depalmitoylation by thioesterases, and evaluation of pot

42 Loss of R-Ras depalmitoylation caused by APT-1 deficiency constrained

43 reveal that targeting LYPLAL1-mediated cGAS depalmitoylation contributes to cGAS activation, providi

44 To evaluate the palmitoylation/depalmitoylation cycle as a candidate drug target in an

45 This palmitoylation-depalmitoylation cycle enhances STAT3 activation and pro

46 Specifically, inhibiting the palmitoylation/depalmitoylation cycle is an appealing strategy for trea

47 Thus, the S-palmitoylation-depalmitoylation cycle mediated by DHHC7 and APT2 specif

48 The palmitoylation/depalmitoylation cycle of posttranslational processing i

49 unique to KRAS4A because the palmitoylation-depalmitoylation cycle of this RAS isoform enables coloc

50 AT3 binding by inhibiting the palmitoylation-depalmitoylation cycle suppressed T(H)17 cell differenti

51 e of this modification is the palmitoylation-depalmitoylation cycle that regulates the subcellular tr

52 including N-Ras, depend on a palmitoylation/depalmitoylation cycle to regulate their subcellular tra

53 teins undergo extremely rapid palmitoylation/depalmitoylation cycles after cellular stimulation suppo

54 ire dynamic S-palmitoylation (palmitoylation-depalmitoylation cycles) for endosomal trafficking to th

55 Interestingly, however, depalmitoylation does not release NMNAT2 from membranes.

56 erases APT1 and APT2 and that palmitoylation/depalmitoylation dynamics are on a time scale similar to

57 Endothelial knockout of the depalmitoylation enzyme APT-1 (acyl-protein thioesterase

58 By identifying APT2 as the MC1R depalmitoylation enzyme, we are able to demonstrate that

59 Our findings indicate that the family of depalmitoylation enzymes may be substantially broader th

60 new cysteine-based catalytic mechanism for S-depalmitoylation enzymes.

61 However, palmitoylated proteins require depalmitoylation for recycling.

62 dification, these proteins must also undergo depalmitoylation for their degradation by lysosomal prot

63 ire dynamic S-palmitoylation (palmitoylation-depalmitoylation) for trafficking to their destination.

64 of enzymes that catalyze palmitoylation and depalmitoylation has been connected to the development o

65 acyl thioesterases that control ion channel depalmitoylation have not been identified.

66 s, and show that this compound impairs N-Ras depalmitoylation in human acute myeloid leukemia (AML) c

67 ction of Cln5, emphasize the importance of S-depalmitoylation in neuronal homeostasis, and disclose a

68 strategy is programmable allowing selective depalmitoylation in specific organelles, triggered by ce

69 However, the role of protein depalmitoylation in synaptic maturation is unknown.

70 Depalmitoylation-induced changes in the NMDAR pharmacolo

71 Depalmitoylation inhibition caused R7BP to redistribute

72 ese data support the clinical development of depalmitoylation inhibitors as a novel class of rational

73 rendered GIRK channel closure insensitive to depalmitoylation inhibitors.

74 d Gibb's free-energy profile suggests that S-depalmitoylation is a rate-limiting step compared to the

75 mammalian genome catalyze S-palmitoylation, depalmitoylation is catalyzed by thioesterases such as P

76 le over 20 palmitoylation enzymes are known, depalmitoylation is conducted by fewer enzymes.

77 In contrast, depalmitoylation is controlled by the cytosolic thioeste

78 at the equilibrium provided by Ppt1-mediated depalmitoylation is critical for AMPA receptor (AMPAR)-m

79 The significance of depalmitoylation is evidenced by the discovery that muta

80 These results suggest that endothelial depalmitoylation is regulated by the metabolic milieu an

81 g to plasmalemmal caveolae; agonist-promoted depalmitoylation leads to eNOS translocation.

82 ming live cell function of Cln5 in setting S-depalmitoylation levels.

83 Inhibiting R7BP depalmitoylation may provide a means of enhancing GIRK a

84 on; perturbation of either palmitoylation or depalmitoylation negatively affects T(H)17 cell differen

85 Depalmitoylation occurred slowly (t(1/2) approximately 2

86 ted with the sequential S-palmitoylation and depalmitoylation of a previously undescribed site of mod

87 One model declares that depalmitoylation of alpha, which accompanies activation

88 This dissociation may involve depalmitoylation of an amino-terminal cysteine residue.

89 PT1 overexpression appears to accelerate the depalmitoylation of eNOS in COS-7 cells cotransfected wi

90 n-eNOS complex, rather than agonist-promoted depalmitoylation of eNOS, relieves caveolin's tonic inhi

91 r of Ras signaling through its modulation of depalmitoylation of H-Ras and its recycling from plasma

92 A cycle of palmitoylation/depalmitoylation of H-Ras mediates bidirectional traffic

93 kdown or inhibition of APT1 and APT2 blocked depalmitoylation of Huntingtin, but did not affect palmi

94 and APT2 are cytosolic enzymes that catalyze depalmitoylation of membrane-anchored, palmitoylated H-R

95 Depalmitoylation of membrane-bound GAP-43 did not releas

96 More important, the APT1-catalyzed depalmitoylation of palmitoyl-eNOS is potentiated by Ca(

97 toyl protein thioesterase(s) responsible for depalmitoylation of plasma membrane-associated signaling

98 iated AMPA receptor internalization requires depalmitoylation of PSD-95.

99 Depalmitoylation of R7BP translocates R7BP-R7-Gbeta5 com

100 Depalmitoylation of Rho at Cys322 and Cys323 altered the

101 PPT1 catalyzes depalmitoylation of S-palmitoylated proteins for degrada

102 -kDa isoform, although it did not accelerate depalmitoylation of sarcolemmal eNOS, as determined by p

103 Depalmitoylation of TEAD is mediated by depalmitoylases

104 In contrast, APT1-catalyzed depalmitoylation of the G protein Galpha(s) is unaffecte

105 Our results show that Wnt5a promotes depalmitoylation of the melanoma cell adhesion molecule

106 Moreover, depalmitoylation of the receptor is regulated by activat

107 oting dynamic palmitoylation (palmitoylation-depalmitoylation) of both thioesterases.

108 Still, the impact of Ppt1-mediated depalmitoylation on synaptic transmission and plasticity

109 ced spine removal of AKAP79/150 required its depalmitoylation on two Cys residues within the N-termin

110 hat the mutants either have a faster rate of depalmitoylation or that they are consumed in a time-dep

111 We confirmed that depalmitoylation plays a role in disulfide bond formatio

112 Selective inhibition of PRDX6 blocks Galphai depalmitoylation, prevents the enhanced receptor G-prote

113 Depalmitoylation produced a weakened interaction with ei

114 The identification of the depalmitoylation reaction of CD95 by APTs as a microRNA

115 Further, chemical depalmitoylation reduces the casein phosphorylation acti

116 Inhibition of depalmitoylation reveals that S-palmitoylation of Cys-26

117 Cysteine depalmitoylation sites in transmembrane PPT1 substrates

118 Additional results show that blockade of depalmitoylation slows the degradation of ARL13b that oc

119 gation of the CSPalpha mutants, and chemical depalmitoylation solubilized the aggregates, demonstrati

120 mutations on both the S-palmitoylation and S-depalmitoylation steps, providing valuable data for the

121 tes fibrosis through pathways independent of depalmitoylation that include interaction with MYO1B to

122 P12 regulates H-Ras trafficking by promoting depalmitoylation through cis-trans isomerization of a pe

123 Ts to directly interact with CD95 to promote depalmitoylation, thus impairing apoptosis mediated thro

124 cilitate GAP action by (i) promoting Gialpha depalmitoylation to create optimal GAP substrates, and (

125 almitoylation is held in delicate balance by depalmitoylation to precisely regulate protein turnover.

126 mal GAP substrates, and (ii) inhibiting R7BP depalmitoylation to stabilize membrane association of R7

127 lipid rafts by pharmacological inhibition of depalmitoylation virtually abolished CD44-ezrin interact

128 Notably, such LTD-induced depalmitoylation was also blocked by CaMKII inhibition.

129 nucleus; and G(i/o) signaling inhibits R7BP depalmitoylation whereas G(i/o) inactivation induces nuc

130 provide evidence that Wnt5a induces protein depalmitoylation, which promotes polarized protein local

131 validated putative substrates through direct depalmitoylation with recombinant PPT1.

132 ential mechanism, perhaps involving receptor depalmitoylation, with phosphorylation at Thr(318) being